FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma

Cancer Research

Volumn 64, Issue 6, 2004, Pages 1911-1914

  Van Rhijn, Bas W G ^a,b   Van Der Kwast, Theo H ^a   Vis, André N ^a,b   Kirkels, Wim J ^b   Boevé, Egbert R ^c   Jöbsis, Adriaan C ^c   Zwarthoff, Ellen C ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELIC EXCLUSION; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CARCINOMA CELL; CONTROLLED STUDY; DISEASE COURSE; FGFR3 GENE; GENE; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR; UROTHELIAL CELL CARCINOMA;

AGED; FEMALE; GENES, P53; HUMANS; MALE; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 1542405934     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2421     Document Type: Article

References (21)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-41.
3. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N. Engl J Med 1990;322:1129-38.
4. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993;342:469-71.
5. Spruck, C. H. III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
6. Primdahl H, von der Maase H, Christensen M, Wolf H, Orntoft TF. Allelic deletions of cell growth regulators during progression of bladder cancer. Cancer Res 2000;60: 6623-9.
7. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000;9:2973-80.
8. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809-18.
9. van Rhijn BW, Lurkin I, Chopin DK, et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003;9:257-63.
10. Capellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
11. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001;20:4416-8.
12. Karoui M, Hofmann-Radvanyi H, Zimmermann U, et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001;20:5059-61.
13. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-8.
14. Billerey C, Chopin D, Aubriot-Lorton, M-H, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.
15. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer (Phila.) 2001;92:2555-61.
16. Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter V, Cordon-Cardo C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 1994;54:2848-51.
17. Cote RJ, Datar RH. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol/Hematol 2003;46 Suppl:S67-83.
18. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathelogic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21.
19. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-12.
20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
21. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002;99:9433-8.